Dataset from Allogeneic Hematopoietic Cell Transplant for Hematological Cancers and Myelodysplastic Syndromes in HIV-Infected Individuals (BMT CTN #0903)

The rationale for this trial is to demonstrate the feasibility and safety of allogeneic HCT
for patients with chemotherapy-sensitive hematological malignancies and coincident
HIV-infection. In particular, the trial will focus on the 100-day non-relapse mortality as an
indicator of the safety of transplant in this patient population. Correlative assays will
focus upon the incidence of infectious complications in this patient population, the
evolution of HIV infection and immunological reconstitution. Where feasible (and when this
can be accomplished without compromise of either the donor quality or the timeliness of
transplantation), an attempt will be made to identify donors who are homozygotes for the
delta32 mutation for CCR5.